ContraFect (NASDAQ:CFRX) Upgraded by WBB Securities to Strong-Buy

ContraFect (NASDAQ:CFRX – Get Rating) was upgraded by analysts at WBB Securities to a “strong-buy” rating in a research note issued on Wednesday, Stock Target Advisor reports. The firm presently has a $7.00 target price on the biotechnology company’s stock. WBB Securities’ price objective points to a potential upside of 104.68% from the company’s current […]

Related Keywords

United States , ,Contrafect Corporation ,Wealthtrust Axiom ,Contrafect Company Profile Get Rating ,Nasdaq ,Capital Management ,Acadian Asset Management ,Avantax Advisory Services Inc ,Moody Lynn Lieberson ,Get Rating ,Stock Target Advisor ,Asset Management ,Trust Axiom ,Avantax Advisory Services ,Advisory Services ,Fect Company Profile ,Fect Corporation ,Target Advisor ,Contrafect ,Nasdaq Cfrx ,Cfrx ,Medical ,Upgrade ,Wbb Securities ,